DOCSLIB.ORG

The Two Tontti Tudiul Lui Hi Ha Unit

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Two Tontti Tudiul Lui Hi Ha Unit THETWO TONTTI USTUDIUL 20170267753A1 LUI HI HA UNIT ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2017 /0267753 A1 Ehrenpreis (43 ) Pub . Date : Sep . 21 , 2017 ( 54 ) COMBINATION THERAPY FOR (52 ) U .S . CI. CO - ADMINISTRATION OF MONOCLONAL CPC .. .. CO7K 16 / 241 ( 2013 .01 ) ; A61K 39 / 3955 ANTIBODIES ( 2013 .01 ) ; A61K 31 /4706 ( 2013 .01 ) ; A61K 31 / 165 ( 2013 .01 ) ; CO7K 2317 /21 (2013 . 01 ) ; (71 ) Applicant: Eli D Ehrenpreis , Skokie , IL (US ) CO7K 2317/ 24 ( 2013. 01 ) ; A61K 2039/ 505 ( 2013 .01 ) (72 ) Inventor : Eli D Ehrenpreis, Skokie , IL (US ) (57 ) ABSTRACT Disclosed are methods for enhancing the efficacy of mono (21 ) Appl. No. : 15 /605 ,212 clonal antibody therapy , which entails co - administering a therapeutic monoclonal antibody , or a functional fragment (22 ) Filed : May 25 , 2017 thereof, and an effective amount of colchicine or hydroxy chloroquine , or a combination thereof, to a patient in need Related U . S . Application Data thereof . Also disclosed are methods of prolonging or increasing the time a monoclonal antibody remains in the (63 ) Continuation - in - part of application No . 14 / 947 , 193 , circulation of a patient, which entails co - administering a filed on Nov. 20 , 2015 . therapeutic monoclonal antibody , or a functional fragment ( 60 ) Provisional application No . 62/ 082, 682 , filed on Nov . of the monoclonal antibody , and an effective amount of 21 , 2014 . colchicine or hydroxychloroquine , or a combination thereof, to a patient in need thereof, wherein the time themonoclonal antibody remains in the circulation ( e . g . , blood serum ) of the Publication Classification patient is increased relative to the same regimen of admin (51 ) Int . Cl. istration of the monoclonal antibody but without the co COOK 16 / 24 ( 2006 .01 ) administration of the effective amount of colchicine and /or A61K 31 /4706 ( 2006 .01 ) hydroxychloroquine. Further disclosed are therapeutic com A61K 31 / 165 ( 2006 . 01 ) binations, and kits containing the monoclonal antibodies and A61K 39 /395 ( 2006 .01 ) hydroxychloroquine and / or colchicine . US 2017 /0267753 A1 Sep . 21, 2017 COMBINATION THERAPY FOR [ 0004 ] It is therefore of high importance to develop meth CO -ADMINISTRATION OF MONOCLONAL ods to prevent ADA development in patients receiving ANTIBODIES biologic therapy that are safer than those that are currently in practice . CROSS -REFERENCE TO RELATED APPLICATIONS SUMMARY [0005 ] Broadly , the present invention is based on the [0001 ] This application is a continuation - in - part of U . S . unexpected discovery that colchicine and hydroxychloro patent application Ser . No . 14 / 947, 193 , filed Nov . 20 , 2015 , quine increase the time that a monoclonal antibody remains which claims the benefit of U . S . Provisional Application No . in the circulation or circulatory system ( e . g . , blood serum ) of 62 /082 ,692 , filed Nov. 21 , 2014 . The disclosures of each of a patient by reducing the clearance of the monoclonal these are incorporated herein by reference in their entireties antibody from the body . The co - administration of colchicine for all purposes. and hydroxychloroquine and a monoclonal antibody thus increase the clearance time ofmonoclonal antibody from the BACKGROUND body . Unlike known and conventional attempts to increase the effectiveness of monoclonal antibody therapies by pre 10002 ] Monoclonal antibodies have been developed for venting the formation of HACAs and other anti -drug anti the treatment of a variety of conditions including autoim bodies ( such as immunosuppression ) , the present invention mune disorders , cancer , asthma, hypercholesterolemia and may mitigate or even eliminate one of more of these sepsis . The development of therapeutic monoclonal antibod drawbacks . ies in these areas of medicine has progressed at a rapid pace . [0006 ] Accordingly , a first aspect of the present invention The number of new biologic agents that have been approved is directed to a method for enhancing the efficacy of mono by the Food and Drug Administration (FDA ) each year has clonal antibody therapy , which entails co -administering a quadrupled between 2004 and 2008 . This relatively new therapeutic monoclonal antibody , or a functional fragment class of medications has resulted in marked improvement in thereof, and an effective amount of colchicine or hydroxy a number of patients with complex and potentially life chloroquine , or a combination thereof, to a patient in need threatening conditions , and in some cases , they have thereof. replaced traditional small molecule pharmaceuticals as treat 10007 ] A related aspect of the present invention is directed ments of choice . These medications also accounted for to a method of prolonging or increasing the time a thera approximately 17 % of total global spending on medicines in peutic monoclonal antibody remains in the circulation or 2016 with an overall market value of $ 200 billion . circulatory system of a patient, which entails co -adminis [ 0003 ] An important influence on the utility of biologic tering an effective amount of a therapeutic monoclonal therapy in an individual patient is the development of antibody, or a functional fragment thereof, and an effective anti - drug antibodies ( ADA ) . ADAs have been documented amount of colchicine, hydroxychloroquine , or a combina in patients receiving multiple doses of a variety monoclonal tion thereof, to a patient in need thereof. Clearance time of antibodies , including infliximab ( IFX ) , a treatment for the monoclonal antibody from the circulation ( e . g . , blood inflammatory bowel disease , rheumatoid arthritis , psoriatic serum ) of the patient is increased relative to the same arthritis and other autoimmune diseases . The development regimen of administration of the monoclonal antibody but of ADAs to IFX , as well as other monoclonal antibodies, is without the co -administration of the effective amount of associated with systemic reactions that can occur during or colchicine and /or hydroxychloroquine . within a few days of drug infusion . When severe , they can [0008 ] Another aspect of the present invention is directed require discontinuation of biologic therapies . In addition , a to a therapeutic combination , which includes a therapeuti number of studies have shown that ADAs reduce the efficacy cally effective amount of a monoclonal antibody, and an of biologic therapy. From a pharmacokinetic standpoint, effective amount of colchicine or hydroxychloroquine , or a ADAs have been shown to enhance the clearance of biologic combination thereof. medications . Strategies that have been developed to prevent [0009 ] A further aspect of the present invention is directed ADA formation and their negative effect on the efficacy of to a kit , which includes a therapeutic combination , which biologic therapies include adherence to consistent timing of includes a therapeutically effective amount of a monoclonal drug infusions or subcutaneous injection regimens, and the antibody , and an effective amount of colchicine or hydroxy co - administration of oral immunomodulating medications chloroquine , or a combination thereof. The kit may include such as thiopurines (azathioprine or its precursor agent both agents in a single dosage form or in separate dosage 6 -mercaptopurine ) , and methotrexate . Although studies have forms, in which case the respective dosage forms may be shown that this strategy of co -administration of the afore disposed in separate containers in the kit . The kit may further mentioned immunomodulating agents reduces ADA produc include printed instructions for using the therapeutic com tion , rapid clearance of biologic agents and infusion reac bination to practice the methods described herein . tions, patients on both classes of drugs may become further [0010 ] In some embodiments of these aspects of the immunosuppressed , placing them at increased risk for present invention , the monoclonal antibody is chronically opportunistic infections, tuberculosis , overwhelming fungal administered ( over a prolonged period of time) such as in the infections and a variety of cancers . In fact, hepatosplenic case of treatment of auto - immune diseases , e . g . , monoclonal T - cell lymphoma, a rare , deadly cancer seen primarily in antibodies that target ( and thus inhibit ) TNF - a , such as young males with Crohn ' s disease , has only been described adalimumab , certolizumab pegol, golimumab , and inflix in patients receiving monoclonal antibodies (MAD ) against imab . tumor necrosis factor alpha ( TNF - a ) in combination with 0011 ] Hydroxychloroquine has a long history of use as an thiopurine drugs . anti -malarial drug . Clinical studies have shown that US 2017 /0267753 A1 Sep . 21, 2017 hydroxychloroquine is not effective as a treatment for IBD , decreasing the removal of the monoclonal antibody from the cancer, Clostridium infection , sepsis ( except due to malaria ), circulation . It is also believed that hydroxychloroquine asthma or hyperchloresterolemia . Hydroxychloroquine is raises lysosomal pH , which causes disruption of lysososmal used as a disease -modifying anti - rheumatic drug in the function such as processing of antigens ( such as monoclonal treatment of rheumatoid arthritis and is commonly employed proteins ) and antigen presentation to mononuclear cells . as treatment for systemic lupus erythematosis . Thus , hydroxychloroquine is effective treatment for several disor ders . However, its specific
Load more

Recommended publications
  • ( 12 ) Patent Application Publication ( 10 ) Pub . No .: US 2020/0121788 A1
    US 20200121788A1 IN (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No .: US 2020/0121788 A1 MASSIMINI et al. (43 ) Pub . Date : Apr. 23 , 2020 ( 54 ) ABITUZUMAB FOR THE TREATMENT OF A61K 31/44 (2006.01 ) COLORECTAL CANCER A61P 35/00 (2006.01 ) (52 ) U.S. Cl. ( 71) Applicant: Merck Patent GmbH , Darmstadt (DE ) CPC ... A61K 39/39558 (2013.01 ) ; CO7K 16/2848 ( 2013.01 ) ; CO7K 16/2863 ( 2013.01 ) ; CO7K ( 72 ) Inventors: Giorgio MASSIMINI, Darmstadt (DE ) ; 16/22 (2013.01 ) ; A61K 31/4745 ( 2013.01 ) ; Ilhan Celik , Zwingenberg (DE ) ; Josef A61K 31/513 ( 2013.01 ) ; A61K 2039/505 Straub , Seeheim - Jugenheim (DE ) ; Rolf ( 2013.01) ; A61K 31/519 ( 2013.01 ) ; A61K Bruns, Darmstadt ( DE ) 33/243 (2019.01 ) ; A6IK 38/179 ( 2013.01) ; A61K 31/44 ( 2013.01) ; A61P 35/00 ( 2018.01 ) ; ( 73 ) Assignee: Merck Patent GmbH , Darmstadt (DE ) CO7K 2317/76 ( 2013.01) ; A61K 31/7072 ( 21 ) Appl. No .: 16 /657,828 ( 2013.01) ( 22 ) Filed : Oct. 18 , 2019 (57 ) ABSTRACT Methods of treatment of colorectal cancer can include the Related U.S. Application Data administration of the anti - alpha - v integrin (receptor ) anti (60 ) Provisional application No. 62 / 748,114 , filed on Oct. body Abituzumab . Preferably , the methods of treating col 19 , 2018 . orectal cancer can include treating Stage II - IV colorectal cancer, metastatic colorectal cancer , left - sided colorectal Publication Classification cancer and /or left- sided metastatic colorectal cancer, involv ( 51) Int. Ci. ing the administration of said Abituzumab to patients in need A61K 39/395 ( 2006.01 ) thereof. Abituzumab is also useful for the manufacture of a COZK 16/28 ( 2006.01 ) medicament for treating colorectal cancer , preferably col COOK 16/22 ( 2006.01 ) orectal cancer as defined herein .
    [Show full text]
  • Fig. L COMPOSITIONS and METHODS to INHIBIT STEM CELL and PROGENITOR CELL BINDING to LYMPHOID TISSUE and for REGENERATING GERMINAL CENTERS in LYMPHATIC TISSUES
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date Χ 23 February 2012 (23.02.2012) WO 2U12/U24519ft ft A2 (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, A61K 31/00 (2006.01) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, PCT/US201 1/048297 KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (22) International Filing Date: ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, 18 August 201 1 (18.08.201 1) NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (25) Filing Language: English TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (26) Publication Language: English ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/374,943 18 August 2010 (18.08.2010) US kind of regional protection available): ARIPO (BW, GH, 61/441,485 10 February 201 1 (10.02.201 1) US GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, 61/449,372 4 March 201 1 (04.03.201 1) US ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (72) Inventor; and EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, ΓΓ, LT, LU, (71) Applicant : DEISHER, Theresa [US/US]; 1420 Fifth LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, Avenue, Seattle, WA 98101 (US).
    [Show full text]
  • Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
    Predictive QSAR tools to aid in early process development of monoclonal antibodies John Micael Andreas Karlberg Published work submitted to Newcastle University for the degree of Doctor of Philosophy in the School of Engineering November 2019 Abstract Monoclonal antibodies (mAbs) have become one of the fastest growing markets for diagnostic and therapeutic treatments over the last 30 years with a global sales revenue around $89 billion reported in 2017. A popular framework widely used in pharmaceutical industries for designing manufacturing processes for mAbs is Quality by Design (QbD) due to providing a structured and systematic approach in investigation and screening process parameters that might influence the product quality. However, due to the large number of product quality attributes (CQAs) and process parameters that exist in an mAb process platform, extensive investigation is needed to characterise their impact on the product quality which makes the process development costly and time consuming. There is thus an urgent need for methods and tools that can be used for early risk-based selection of critical product properties and process factors to reduce the number of potential factors that have to be investigated, thereby aiding in speeding up the process development and reduce costs. In this study, a framework for predictive model development based on Quantitative Structure- Activity Relationship (QSAR) modelling was developed to link structural features and properties of mAbs to Hydrophobic Interaction Chromatography (HIC) retention times and expressed mAb yield from HEK cells. Model development was based on a structured approach for incremental model refinement and evaluation that aided in increasing model performance until becoming acceptable in accordance to the OECD guidelines for QSAR models.
    [Show full text]
  • Andrew Lai Thesis
    TOWARDS THE DEVELOPMENT OF NOVEL BISPECIFIC ANTIBODIES TO INHIBIT KEY CELL SURFACE RECEPTORS INTEGRAL FOR THE GROWTH AND MIGRATION OF TUMOUR CELLS Andrew Lai Bachelor of Science, UNSW 2008 Master of Biotechnology, QUT 2010 Bachelor of Applied Science (Hons), QUT 2012 Submitted for the degree of Doctor of Philosophy Institute of Health and Biomedical Innovation Faculty of Health Queensland University of Technology 2016 Keywords Breast cancer, extracellular matrix, insulin-like growth factor, metastasis, migration, therapeutics, phage display, single chain variable fragments, vitronectin Towards the development of novel bispecific antibodies to inhibit key cell surface receptors integral for the growth and migration of tumour cells i Abstract Metastatic breast cancer, or breast cancer which has spread from the primary tumour to distal secondary sites, remains a major killer of women today. Researchers have observed that the relationship between tumour cells and its surrounding environment plays an important role in cancer progression. One such interaction is between the Insulin-like growth factor (IGF) system and the integrin system, which has been demonstrated to be involved in cancer cell metabolic activity and migration. Therefore, the aim of this project was to translate this knowledge into the generation of bispecific antibody fragments (BsAb) targeting both systems, in order to disrupt their roles in cancer growth and metastasis. To screen for IGF-1R and αv integrin binding ScFv, a phage display enrichment procedure using the Tomlinson ScFv libraries was conducted. After the panning cycles, 192 clones were screened for binding using ELISA, of which 16 were selected for sequencing. Analysis of the results revealed 1 IGF-R and 3 αv integrin unique binding ScFv, which were all subsequently expressed in a bacterial expression system.
    [Show full text]
  • Antibody Drug Conjugate Development in Gastrointestinal Cancers: Hopes and Hurdles from Clinical Trials
    Wu et al. Cancer Drug Resist 2018;1:204-18 Cancer DOI: 10.20517/cdr.2018.16 Drug Resistance Review Open Access Antibody drug conjugate development in gastrointestinal cancers: hopes and hurdles from clinical trials Xiaorong Wu, Thomas Kilpatrick, Ian Chau Department of Medical oncology, Royal Marsden Hospital NHS foundation trust, Sutton SM2 5PT, UK. Correspondence to: Dr. Ian Chau, Department of Medical Oncology, Royal Marsden Hospital NHS foundation trust, Downs Road, Sutton SM2 5PT, UK. E-mail: [email protected] How to cite this article: Wu X, Kilpatrick T, Chau I. Antibody drug conjugate development in gastrointestinal cancers: hopes and hurdles from clinical trials. Cancer Drug Resist 2018;1:204-18. http://dx.doi.org/10.20517/cdr.2018.16 Received: 31 Aug 2018 First Decision: 8 Oct 2018 Revised: 13 Nov 2018 Accepted: 16 Nov 2018 Published: 19 Dec 2018 Science Editors: Elisa Giovannetti, Jose A. Rodriguez Copy Editor: Cui Yu Production Editor: Huan-Liang Wu Abstract Gastrointestinal (GI) cancers represent the leading cause of cancer-related mortality worldwide. Antibody drug conjugates (ADCs) are a rapidly growing new class of anti-cancer agents which may improve GI cancer patient survival. ADCs combine tumour-antigen specific antibodies with cytotoxic drugs to deliver tumour cell specific chemotherapy. Currently, only two ADCs [brentuximab vedotin and trastuzumab emtansine (T-DM1)] have been Food and Drug Administration approved for the treatment of lymphoma and metastatic breast cancer, respectively. Clinical research evaluating ADCs in GI cancers has shown limited success. In this review, we will retrace the relevant clinical trials investigating ADCs in GI cancers, especially ADCs targeting human epidermal growth receptor 2, mesothelin, guanylyl cyclase C, carcinogenic antigen-related cell adhesion molecule 5 (also known as CEACAM5) and other GI malignancy specific targets.
    [Show full text]
  • Immunotherapy in Various Cancers
    © 2021 JETIR June 2021, Volume 8, Issue 6 www.jetir.org (ISSN-2349-5162) Immunotherapy in various Cancers Nirav Parmar 1st Year MSc Student Department of Biosciences and Bioengineering, IIT- Roorkee India Abstract: Immunotherapy in the metastatic situation has changed the therapeutic landscape for a variety of cancers, including colorectal cancer. Immunotherapy has firmly established itself as a new pillar of cancer treatment in a variety of cancer types, from the metastatic stage to adjuvant and neoadjuvant settings. Immune checkpoint inhibitors have risen to prominence as a treatment option based on a better knowledge of the development of the tumour microenvironment immune cell-cancer cell regulation over time. Immunotherapy has lately appeared as the most potential field of cancer research by increasing effectiveness and reducing side effects, with FDA-approved therapies for more than 10 various tumours and thousands of new clinical studies. Key Words: Immunotherapy, metastasis, immune checkpoint. Introduction: In the late 1800s, William B. Coley, now generally regarded as the founder of immunotherapy, tried to harness the ability of immune system to cure cancer for the first time. Coley began injecting live and attenuated bacteria like Streptococcus pyogenes and Serratia marcescens into over a thousand patients in 1891 in the hopes of causing sepsis and significant immunological and antitumor responses. His bacterium mixture became known as "Coley's toxin" and is the first recorded active cancer immunotherapy treatment [1]. To better understand the processes of new and traditional immunological targets, the relationship between the immune system and tumour cells should be examined. Tumours have developed ways to evade immunological responses.
    [Show full text]
  • Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix
    United States International Trade Commission Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix USITC Publication 4208 December 2010 U.S. International Trade Commission COMMISSIONERS Deanna Tanner Okun, Chairman Irving A. Williamson, Vice Chairman Charlotte R. Lane Daniel R. Pearson Shara L. Aranoff Dean A. Pinkert Address all communications to Secretary to the Commission United States International Trade Commission Washington, DC 20436 U.S. International Trade Commission Washington, DC 20436 www.usitc.gov Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix Publication 4208 December 2010 (This page is intentionally blank) Pursuant to the letter of request from the United States Trade Representative of December 15, 2010, set forth at the end of this publication, and pursuant to section 1207(a) of the Omnibus Trade and Competitiveness Act, the United States International Trade Commission is publishing the following modifications to the Harmonized Tariff Schedule of the United States (HTS) to implement changes to the Pharmaceutical Appendix, effective on January 1, 2011. Table 1 International Nonproprietary Name (INN) products proposed for addition to the Pharmaceutical Appendix to the Harmonized Tariff Schedule INN CAS Number Abagovomab 792921-10-9 Aclidinium Bromide 320345-99-1 Aderbasib 791828-58-5 Adipiplon 840486-93-3 Adoprazine 222551-17-9 Afimoxifene 68392-35-8 Aflibercept 862111-32-8 Agatolimod
    [Show full text]
  • The Pipeline Report 2016 Pipeline 2014 Autoimmune
    THE PIPELINE REPORT 2016 PIPELINE 2014 AUTOIMMUNE PRODUCTS GENERATING BUZZ OTHER KEY PRODUCTS IN THE PIPELINE BIG-TIME Baricitinib Eli Lilly/Incyte Indication: RA (Ph.III) Romosozumab Amgen/UCB Sirukumab Janssen Biotech RA What the clinical trials found: The daily oral demonstrated superiority Osteoporosis (Ph.III) (Ph.III) compared to placebo after 12 weeks based on ACR20 response (Ph. Avatrombopag Astellas Pharma Anifrolumab Medarex/Med­ III RA-BEAM). The agent also proved superior to adalimumab on ITP/thrombocytopenia (Ph.III) Immune Systemic lupus erythema- tosus (Ph.III) key secondary objectives of ACR20 response and improvement in Elobixibat AstraZeneca CIC and DAS28-hsCRP score. A few occasional AEs were reported. IBS-C (Ph.III) Odanacatib Merck Osteoporosis (Ph.III) Credit Suisse Success Probability and inThought Comment: 70%. Lesinurad AstraZeneca Gout (Ph. III) Tildrakizumab Merck Psoriasis The JAK inhibitor appears to have similar efficacy and safety to (Ph.III) Pfizer’s Xeljanz. It was supposed to have a once daily vs. Xeljanz’s Alicaforsen Atlantic Healthcare Pouchitis/ulcerative colitis (Ph.III) Siponimod Novartis MS (Ph.III) twice daily advantage, but Xeljanz’s once daily formulation will likely be approved soon. It’ll be interesting to see if Lilly/Incyte Rituximab biosimilar Boehringer Infliximab biosimilar Pfizer RA Ingelheim RA (Ph.III) (Ph.III) can do something with patient access and price to improve upon Mongersen Celgene/Nogra RHB 104 RedHill Biopharma the poor performance of Xeljanz and expand the JAK inhibitor Pharma Crohn’s disease (Ph.III) Crohn’s disease (Ph.III) market. Expected launch: 2016 (Source: Credit Suisse) Etanercept biosimilar Coherus Sarilumad Regeneron RA (Ph.III) Credit Suisse forecast: $1.09 billion in global annual sales by 2020 Biosciences/Daiichi Sankyo/ Etrolizumab Roche Ulcerative A peek at 159 aspiring agents, with profiles on 17 that could shoot to stardom.
    [Show full text]
  • Preclinical Efficacy of an Antibody–Drug Conjugate Targeting
    Published OnlineFirst October 19, 2016; DOI: 10.1158/1535-7163.MCT-16-0449 Large Molecule Therapeutics Molecular Cancer Therapeutics Preclinical Efficacy of an Antibody–Drug Conjugate Targeting Mesothelin Correlates with Quantitative 89Zr-ImmunoPET Anton G.T. Terwisscha van Scheltinga1,2, Annie Ogasawara1, Glenn Pacheco1, Alexander N. Vanderbilt1, Jeff N. Tinianow1, Nidhi Gupta1, Dongwei Li1, Ron Firestein1, Jan Marik1, Suzie J. Scales1, and Simon-Peter Williams1 Abstract Antibody–drug conjugates (ADC) use monoclonal antibo- and HPAF-II, or mesothelioma MSTO-211H. Ex vivo analysis dies (mAb) as vehicles to deliver potent cytotoxic drugs selec- of mesothelin expression was performed using immunohis- tively to tumor cells expressing the target. Molecular imaging tochemistry. AMA-MMAE showed the greatest growth inhibi- with zirconium-89 (89Zr)-labeled mAbs recapitulates similar tion in OVCAR-3Â2.1, Capan-2, and HPAC tumors, which targeting biology and might help predict the efficacy of these showed target-specific tumor uptake of 89Zr-AMA. The less ADCs. An anti-mesothelin antibody (AMA, MMOT0530A) was responsive xenografts (AsPC-1, HPAF-II, and MSTO-211H) did used to make comparisons between its efficacy as an ADC and not show 89Zr-AMA uptake despite confirmed mesothelin its tumor uptake as measured by 89Zr immunoPET imaging. expression. ImmunoPET can demonstrate the necessary deliv- Mesothelin-targeted tumor growth inhibition by monomethyl ery, binding, and internalization of an ADC antibody in vivo auristatin E (MMAE), ADC AMA-MMAE (DMOT4039A), andthiscorrelateswiththeefficacy of mesothelin-targeted ADC was measured in mice bearing xenografts of ovarian cancer in tumors vulnerable to the cytotoxic drug delivered. Mol Cancer OVCAR-3Â2.1, pancreatic cancers Capan-2, HPAC, AsPC-1, Ther; 16(1); 134–42.
    [Show full text]
  • Letter to FDA on Review of Biogen's Drug
    June 2, 2021 Janet Woodcock, M.D. Acting Commissioner of Food and Drugs Food and Drug Administration 10903 New Hampshire Ave Silver Spring, MD 20993-0002 RE: Food and Drug Administration’s Review of Biogen’s drug Aducanumab for Alzheimer’s disease Dear Acting Commissioner Woodcock: The American Geriatrics Society (AGS), an organization dedicated to improving the health and quality of life of all older adults, is writing to express our concern that the Food and Drug Administration’s (FDA) upcoming review and potential approval of Aducanumab for use in treating patients with mild cognitive impairment (MCI) and Alzheimer’s disease (AD) is premature given the lack of sufficient evidence to support that Aducanumab reduces progression of Alzheimer’s disease and that the potential benefits as a treatment for patients with MCI and AD could outweigh the potential harms. The AGS is a not-for-profit organization comprised of nearly 6,000 geriatrics health professionals who are devoted to improving the health, independence, and quality of life of all older adults. Our members include geriatricians, geriatrics nurse practitioners, social workers, family practitioners, physician assistants, pharmacists, and internists who are pioneers in advanced-illness care for older individuals, with a focus on championing interprofessional teams, eliciting personal care goals, and treating older people as whole persons. We provide leadership to healthcare professionals, policymakers, and the public by implementing and advocating for programs in patient care, research, professional and public education, and public policy. We are familiar with the information that has been released to date. Aducanumab, a human monoclonal antibody developed by Biogen, was assessed in two identical phase III randomized controlled trials, ENGAGE and EMERGE, planned to provide 18-month outcome data in patients with MCI and AD, all with positive amyloid PET scans.
    [Show full text]
  • Patient Resource Free
    PATIENT RESOURCE FREE Third Edition CancerUnderstanding Immunotherapy Published in partnership with CONTENT REVIEWED BY A DISTINGUISHED PRP MEDICAL PATIENT ADVISORY RESOURCE BOARD PUBLISHING® Understanding TABLE OF CONTENTS Cancer Immunotherapy Third Edition IN THIS GUIDE 1 Immunotherapy Today 2 The Immune System 4 Immunotherapy Strategies 6 Melanoma Survivor Story: Jane McNee Chief Executive Officer Mark A. Uhlig I didn’t look sick, so I didn’t want to act sick. Publisher Linette Atwood Having and treating cancer is only one part of your life. Co-Editor-in-Chief Charles M. Balch, MD, FACS Jane McNee, melanoma survivor Co-Editor-in-Chief Howard L. Kaufman, MD, FACS Senior Vice President Debby Easum 7 The Road to Immunotherapy Vice President, Operations Leann Sandifar 8 Cancer Types Managing Editor Lori Alexander, MTPW, ELS, MWC™ 14 Side Effects Senior Editors Dana Campbell Colleen Scherer 15 Glossary Graphic Designer Michael St. George 16 About Clinical Trials Medical Illustrator Todd Smith 16 Cancer Immunotherapy Clinical Trials by Disease Production Manager Jennifer Hiltunen 35 Support & Financial Resources Vice Presidents, Amy Galey Business Development Kathy Hungerford 37 Notes Stephanie Myers Kenney Account Executive Melissa Amaya Office Address 8455 Lenexa Drive CO-EDITORS-IN-CHIEF Overland Park, KS 66214 For Additional Information [email protected] Charles M. Balch, MD, FACS Advisory Board Visit our website at Professor of Surgery, The University of Texas PatientResource.com to read bios of MD Anderson Cancer Center our Medical and Patient Advisory Board. Editor-in-Chief, Patient Resource LLC Editor-in-Chief, Annals of Surgical Oncology Past President, Society of Surgical Oncology For Additional Copies: To order additional copies of Patient Resource Cancer Guide: Understanding Cancer Immunotherapy, Howard L.
    [Show full text]
  • WO 2010/142752 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 16 December 2010 (16.12.2010) WO 2010/142752 Al (51) International Patent Classification: nia 94568 (US). ROBARGE, Kirk D. [US/US]; 1679 C07D 213/75 (2006.01) Λ61K 31/4439 (2006.01) 27th Avenue, San Francisco, California 94122 (US). C07D 401/12 (2006.01) A61K 31/444 (2006.01) STANLEY, Mark S. [US/US]; 284 Lauren Avenue, A61K 31/506 (2006.01) A61P 37/04 (2006.01) Pacifica, California 94044 (US). TSUI, Vickie Hsiao- A61K 31/495 (2006.01) Wei [US/US]; 2626 Martinez Avenue, Burlingame, Cali fornia 94010 (US). WILLIAMS, Karen [GB/GB]; 8/9 (21) International Application Number: Spire Green Centre, Flex Meadow, Harlow, Essex CM 19 PCT/EP2010/058128 5TR (GB). ZHANG, Birong [US/US]; 3060 San Andreas (22) International Filing Date: Drive, Union City, California 94587 (US). ZHOU, Aihe 10 June 2010 (10.06.2010) [US/US]; 1361 Stephen Way, San Jose, California 95129 (US). (25) Filing Language: English (74) Agent: KLOSTERMEYER-RAUBER, Doerte; Gren- (26) Publication Language: English zacherstrasse 124, CH-4070 Basel (CH). (30) Priority Data: (81) Designated States (unless otherwise indicated, for every 61/186,322 11 June 2009 ( 11.06.2009) US kind of national protection available): AE, AG, AL, AM, (71) Applicant (for all designated States except US): F. AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, HOFFMANN-LA ROCHE AG [CWCH]; Grenzacher- CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, strasse 124, CH-4070 Basel (CH).
    [Show full text]